跳至主要内容
临床试验/ACTRN12621000685819
ACTRN12621000685819尚未招募1 期

The effect of sodium-glucose co-transporter 2 inhibition prior to atrial fibrillation ablation on electrophysiological and clinical markers of atrial fibrillation: A pilot randomised controlled trial.

Flinders University0 个研究点目标入组 60 人开始时间: 2021年6月4日最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Patients referred for clinically indicated AF ablation

排除标准

  • People under the age of 18.
  • Patients who are unable or unwilling to provide consent.
  • Considerations related to AF ablation procedure (presence of left atrial thrombus, previous AF ablation, contraindication to anticoagulation).
  • Exclusions related to SGLT2 commencement; patients already taking SGLT2 inhibitors, history of impaired kidney function (eGFR <45mL/min/1.73m2), Child-Pugh Class C liver disease, pregnancy/ breastfeeding, symptomatic hypotension/ systolic blood pressure <100mmHg, type 1 diabetes mellitus, or previous SGLT2 intolerance or allergy, in line with current published contraindications to therapy.

研究者

相似试验